Fig. 4: Survival outcome measures. | British Journal of Cancer

Fig. 4: Survival outcome measures.

From: Critical evaluation of molecular tumour board outcomes following 2 years of clinical practice in a Comprehensive Cancer Centre

Fig. 4

a Swimmer plot of 43 patients receiving an MTB-recommended therapy with available follow-up data. Blue bars indicate the duration of MTB-recommended therapy. b Comparison of the frequency of PFS2/1 ratios ≥1.3 and <1.3 between MTB-recommended and alternative therapies in evaluable patients. Progression-free survival (c) and overall survival (d) over the entire cohort comparing patients receiving MTB-recommended therapies, alternative therapies after the MTB, and patients without further therapies. Progression-free survival (e) and overall survival (f) achieved by tier m1A-based MTB therapies as opposed to all alternative non-MTB-recommended therapies. The P value was calculated by the log-rank test.

Back to article page